HLA-B Antikörper

Produktnummer ABIN3023888

Dieses Maus Monoklonal-Antikörper erkennt spezifisch HLA-B in FACS und IF. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für HLA-B Antikörper (ABIN3023888)

Target: HLA-B (Major Histocompatibility Complex, Class I, B (HLA-B))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser HLA-B Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Immunofluorescence (IF)

Klon: EP-4

Produktdetails anti-HLA-B Antikörper

Produktmerkmale: This mAb recognizes the HLA-B27 cell surface antigen on human cells. It may be used to HLA type human lymphocytes. Approximately 60 % of patients with ankylosing spondylitis are HLA-B27 positive. This reagent can be used to help identify this HLA haplotype in human lymphocytes. Major histocompatibility complex (MHC) molecules form an integral part of the immune response system. They are cell-surface receptors that bind pep- tides and present them to T lymphocytes. Human leukocyte antigens (HLAs) are polymorphic members of the MHC family that are specifically involved in the presentation of antigens to the T cell receptor. There are two classes of HLA antigens: class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D). Class I molecules are expressed in nearly all cells and play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum. The differential structural properties of MHC class I and class II molecules account for their respective roles in activating different populations of T lymphocytes. HLA-B encodes a membrane anchored heavy chain, which hetero-dimerizes with a light chain (b-2-Microglobulin) to form MHC-I. Polymorphisms yield hundreds of HLA-B alleles. The HLA-B27 allele appears with increased frequency in uveitis patients.

Aufreinigung: PEG precipitation

Immunogen: Lymphocytes from an HLA-B27 patient were used as the immunogen for the HLA-B antibody.

Isotyp: IgM kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the HLA-B antibody should be determined by the researcher.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the HLA-B antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Details zu HLA-B

Target: HLA-B (Major Histocompatibility Complex, Class I, B (HLA-B))

Andere Bezeichnung: HLA-B

Hintergrund: This mAb recognizes the HLA-B27 cell surface antigen on human cells. It may be used to HLA type human lymphocytes. Approximately 60 % of patients with ankylosing spondylitis are HLA-B27 positive. This reagent can be used to help identify this HLA haplotype in human lymphocytes. Major histocompatibility complex (MHC) molecules form an integral part of the immune response system. They are cell-surface receptors that bind pep- tides and present them to T lymphocytes. Human leukocyte antigens (HLAs) are polymorphic members of the MHC family that are specifically involved in the presentation of antigens to the T cell receptor. There are two classes of HLA antigens: class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D). Class I molecules are expressed in nearly all cells and play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum. The differential structural properties of MHC class I and class II molecules account for their respective roles in activating different populations of T lymphocytes. HLA-B encodes a membrane anchored heavy chain, which hetero-dimerizes with a light chain (b-2-Microglobulin) to form MHC-I. Polymorphisms yield hundreds of HLA-B alleles. The HLA-B27 allele appears with increased frequency in uveitis patients.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response